Health related quality of life in older patients with solid tumors and prognostic factors for decline

Decoster, Lore; Quinten, Chantal; Kenis, Cindy; Flamaing, Johan; Debruyne, Philip R.; Groof, Inge De; Focan, C.; Cornélis, Frank; Verschaeve, Vincent; Bachmann, Christian; Bron, Dominique; Luce, Sylvie; Debugne, Gwenaëlle; Bulck, den; Baitar, Abdelbari; Geboers, Katrien; Petit, Bénédicte; Langenaeken, Christine; Rijswijk, R. Van; Specenier, Pol; Jérusalem, Guy; Praet, Jean Philippe; Vandenborre, K.; Lobelle, Jean-Pierre; Lycke, Michelle; Milisen, Koen; Wildiers, Hans

doi:10.1016/j.jgo.2019.03.018

Cited by 25 publications

(29 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In line with our findings, various studies have found that, in patients with endometrial cancer or different cancer types, independent of age, comorbidity was associated with poorer HRQoL at baseline or HRQoL deterioration at follow-up [11][12][13]32]. One previous study from our group reported on the association between changes in HRQoL and clinical and sociodemographic characteristics of patients included in the Rogy Care trial and also described the association between cumulative comorbidity burden and poorer HRQoL [12].…”

Section: Discussionsupporting

confidence: 90%

Do age and comorbidity impair recovery during two years after treatment for endometrial cancer?

Walree

Hamaker

Rooij

et al. 2020

Journal of Geriatric Oncology

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 90%

Do age and comorbidity impair recovery during two years after treatment for endometrial cancer?

Walree

Hamaker

Rooij

et al. 2020

Journal of Geriatric Oncology

View full text Add to dashboard Cite

“…For example, a previous study by Decoster et al. (2019) and Quinten et al. (2019) conducted on a larger cohort of older cancer patients demonstrated the prognostic value of GA, in addition to clinical and socio‐demographic variables, in HRQOL decline, a finding that we were not able to replicate in our study.…”

Section: Discussioncontrasting

confidence: 81%

“…A study by Decoster et al. (2019) reported a correlation between GDS and HRQOL, as measured with the EORTC GHS scale. A correlation which our study did not confirm.…”

Section: Discussionmentioning

confidence: 99%

The added value of geriatric assessment in evaluating a patient's Health‐Related Quality‐of‐Life: A study in ≥70‐year‐old early‐stage invasive breast cancer patients

et al. 2020

Self Cite

View full text Add to dashboard Cite

Objective: The objective of this study was to assess the relationship between geriatric assessment (GA) and health-related Quality-of-Life (HRQOL) in older patients with breast cancer. Methods: Patients were assigned either to adjuvant chemotherapy (CTG) or to a control group (CG). Spearman rank coefficients (ρ) calculated correlations between HRQOL and GA at baseline, 3 months and 1 year. Multivariate regressions modelled the prognostic value of GA in evaluating of a patient's HRQOL and the accuracy of baseline GA in predicting HRQOL decline (change of ≥10 points). Results: The analysis included 57 patients in the CTG and 52 in the CG. Strong correlations (ρ ≥ 0.5) were reported between the EORTC QLQ-C30 Physical Functioning Scale and Activities of Daily Living (ADL), Instrumental ADL (iADL) and Leuven Oncogeriatric Frailty Score Scale (LOFS). Multivariate models demonstrated that poor iADL, ADL and LOFS (CG) and ADL and iADL (CTG) contributed to a statistically

show abstract

“…Predictive findings will, therefore, be indicative of a wide range of patients, but the sample size may not be sufficiently large enough to draw conclusions specific to each subgroup. Nevertheless, time of inclusion and planned treatment has not been previously associated with baseline QoL in a study of G8 frail patients [44].…”

Section: Methodological Considerationsmentioning

confidence: 93%

Predictive Value of Geriatric Oncology Screening and Geriatric Assessment in Older Patients with Solid Cancers: Protocol for a Danish prospective cohort study (PROGNOSIS-G8)

Ditzel

Giger

Lund

et al. 2021

Journal of Geriatric Oncology

View full text Add to dashboard Cite

Introduction: Older patients with cancer constitute a heterogeneous group with varying degrees of frailty; therefore, geriatric assessment with initial geriatric oncology screening is recommended. The Geriatric 8 (G8) and the modified Geriatric 8 (mG8) are promising screening tools with high accuracy and an association with survival. However, evidence is sparse regarding patient-centered outcomes. This protocol describes a study, which aims to address the predictive and prognostic value of the G8 and mG8, with quality of life (QoL) as the primary outcome. Materials and methods: In this single-center prospective cohort study, patients, age ≥70 years with solid malignancies, will be screened with the G8 and mG8 prior to receiving 1st line antineoplastic treatment. Patients will contribute medical record data including; cancer type, Charlson comorbidity index score, performance status, and treatment intent, type, and dosage, at baseline. Patients will complete QoL questionnaires (EORTC QLQ-C30 and ELD-14) at baseline, 3, 6, 9, and 12-months follow-up. Two functional measurements (the 30-s chair stand test and the handgrip strength test) will be conducted at baseline to assess the added predictive and prognostic value. At 12 months follow-up, initially administered treatment and treatment adherence will be recorded and assessed with generalized linear models, while overall survival and cancer-specific survival will be assessed using survival analysis models with time-varying covariates. The relationship between frailty (G8 ≤ 14, mG8 ≥ 6) and QoL within 12 months will be examined using mixed regression models. Discussion: Geriatric oncology screening may identify a subgroup of older patients with frailty, at risk of experiencing diminishing QoL and poor treatment adherence. With the proposed screening program, patients who require treatment modification and additional support to maintain their QoL may be identified. It is our hope, that these insights may facilitate the formation of national guidelines for the treatment of older patients with cancer.

show abstract

Health related quality of life in older patients with solid tumors and prognostic factors for decline

Cited by 25 publications

References 44 publications

Do age and comorbidity impair recovery during two years after treatment for endometrial cancer?

Do age and comorbidity impair recovery during two years after treatment for endometrial cancer?

The added value of geriatric assessment in evaluating a patient's Health‐Related Quality‐of‐Life: A study in ≥70‐year‐old early‐stage invasive breast cancer patients

Predictive Value of Geriatric Oncology Screening and Geriatric Assessment in Older Patients with Solid Cancers: Protocol for a Danish prospective cohort study (PROGNOSIS-G8)

Contact Info

Product

Resources

About